Liguzinediol缬氨酸酯前药的设计、合成及成药性评价

李智; 沈敏哲; 李伟; 文红梅; 刘健; 朱浩浩; 钱程博; 蔡建国

Liguzinediol缬氨酸酯前药的设计、合成及成药性评价

南京中医药大学药学院，江苏南京 210023

计量
- 文章访问数: 1524
- HTML全文浏览量: 17
- PDF下载量: 1392
- 被引次数: 0
出版历程
- 收稿日期: 2016-10-19
- 修回日期: 2017-01-07
- 刊出日期: 2017-07-10

Design， Synthesis and Druggability Evaluation of Liguzinediol Valine Ester Prodrug as Promissing Inotropic Agent

摘要

摘要: 目的设计、合成liguzinediol缬氨酸酯前药，结合化学稳定性、理化性质、体外生物转化和体内药代动力学研究，为进一步liguzinediol氨基酸酯类前药研究奠定基础。方法以liguzinediol和N-叔丁氧羰基(Boc)-L-缬氨酸为原料，经4-二甲氨基吡啶（DMAP）催化、N，N'-二环己基碳二亚胺（DCC）缩合成酯，15% TFA脱Boc保护得liguzinediol缬氨酸酯前药，目标化合物结构经LC-HRMS、1H-NMR和13C-NMR确证。采用高效液相色谱法（HPLC）测定目标化合物的化学稳定性、溶解度、容量因子和脂水分配系数，以及体外80%人体血浆中酯酶水解的释放特性和体内药代动力学研究。结果 Liguzinediol缬氨酸酯前药保留了原药的溶解度特性，体外80%人体血浆酶解liguzinediol释放速率良好，体内作用时间明显延长；但脂溶性相对较差。结论 Liguzinediol缬氨酸酯前药具有一定的成药性，且明显延长了原药 liguzinediol的体内作用时间，为进一步liguzinediol氨基酸酯前药研究提供了思路。
- liguzinediol /
- 前药 /
- 理化性质 /
- 药代动力学
Abstract: OBJECTIVE One liguzinediol valine ester prodrug was synthesized and evaluated for the physicochemical properties and bioconversion， which laid the foundation for further study of liguzinediol amino acid ester prodrugs. METHODS Liguzinediol valine ester prodrug was prepared by a two-step reaction of condensation and deprotection from liguzinediol， and its structure was verified by LC-HRMS， 1H-NMR and 13C-NMR. The chemical stability， capacity factor， solubility， lipophilicity， metabolic stability in human plasma and pharmacokinetics study in vivo of valine ester prodrug were tested by HPLC. RESULTS Liguzinediol valine ester prodrug retained great solubility and showed good bioconversion in human plasma. The half-time of liguzinediol was extended obviously. However， the lipophilicity was relatively poor. CONCLUSION Liguzinediol valine ester prodrug was provided with the feature to form the drug， and obvious extended the half-time of liguzinediol. Meanwhile， it indicated that prodrug strategy was feasible， which provided the way of experiment for liguzinediol prodrug research.
- liguzinediol /
- prodrug /
- physicochemical properties /
- pharmacokinetics

HTML全文

参考文献(22)

[1]	刘峥，周淑媛，李伟，等. Liguzinediol对正常大鼠离体心脏的正性肌力作用[J]. 中国新药与临床杂志，2009，28(4)：293-296.
[2]	LIU Z，ZHOU SY，LI W，et al. Liguzinediol induced positive inotropic effect in normal isolated rat hearts[J]. Chin J New Drugs Clin Rem，2009，28(4)：293-296.
[3]	刘峥，卞慧敏，陈龙，等. Liguzinediol正常大鼠心脏血流动力学的影响[J]. 中国药学杂志，2009，44(15)：1155-1158.
[4]	LIU Z，BIAN HM，CHEN L，et al. Effect of liguzinediol on cardiac hemodynamics in healthy rats[J]. Chin Pharm J，2009，44(15)：1155-1158.
[5]	郭瑶，周静，卞慧敏，等. 川芎嗪衍生物 liguzinediol对戊巴比妥钠致急性心力衰竭大鼠血流动力学的影响[J]. 中国实验方剂学杂志，2012，18(6)：170-174.
[6]	GUO Y，ZHOU J，BIAN HM，et al. The effect of liguzinediol on hemodynamics in rats with acute heart failure induced by pentobarbital[J]. Chin J Exp Tradit Med Form，2012，18(6)：170-174.
[7]	章嫡妮，郭瑶，李卓琼，等. Liguzinediol对压力超负荷大鼠心室重构的影响[J]. 中国药理学通报，2012，28(12)：1699-1704.
[8]	ZHANG DN，GUO Y，LI ZQ，et al. Effect of liguzinediol on ventricular remodeling in press-overloaded rats[J]. Chin Pharmacol Bull，2012，28(12)：1699-1704.
[9]	闻侃，刘峥，卞慧敏，等. Liguzinediol的急性毒性[J]. 中国新药与临床杂志，2011，30(3)：234-235.
[10]	WEN K，LIU Z，BIAN HM，et al. Acute toxicity of liguzinediol[J]. Chin J New Drug Clin Rem，2011，30(3)：234-235.
[11]	CHEN L，XU Y，LI W，et al. The novel compound liguzinediol exerts positive inotropic effects in isolated rat heart via sarcoplasmic reticulum Ca2+ ATPase-dependent mechanism[J]. Life Sci，2012，91(11/12)：402-408.
[12]	LARISSA L，ELIE RC，LAHOUARIA H，et al. Sarcoplasmic reticulum Ca2+ ATPase as a therapeutic target for heart failure[J]. Expert Opin Biol Ther，2010，10(1)：29-41.
[13]	SHAN CX，LI W，WEN HM，et al. Identification of liguzinediol metabolities in rats by ultra-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry[J]. J Pharm Biomed Anal，2012，62(3)：187-190.
[14]	LIU Z，LI W，WEN HM， et al. Synthesis， biological evaluation， and pharmacokinetic study of novel LZDO prodrugs[J]. Molecules，2013，18(4)：4561-4572.
[15]	张静，李伟，文红梅，等. Liguzinediol芳酸单酯前药的合成、理化性质及血浆酶解评价[J]. 中国新药杂志，2015，24(3)：325-330.
[16]	ZHANG J，LI W，WEN HM， et al. Synthesis， physicochemical properties and bioconversion of the mono substituted benzoate prodrugs of liguzinediol[J]. Chin New Drug J，2015，24(3)：325-330.
[17]	贾尧玲，王洋. S-[2-(叔丁氧羰基氨基)乙基]-3-苯基丙酸硫酯类化合物脱除Boc保护基的反应研究[J]. 有机化学，2011，31(4)：538-543.
[18]	JIA YL，WANG Y. Study on the deprotection of Boc group of S-2-(tert-Butoxycarbonylamino)ethyl-3-Phenylpropanethioates[J]. Chin J Org Chem，2011，31(4)：538-543.
[19]	IM JS，BALAKRISHNAN P，OH DH，et al. Evaluation of sali-cylic acid fatty ester prodrugs for UV protection[J]. Drug Dev Ind Pharm，2011，37(7)：841-848.
[20]	PENG Y，SUN JG，WANG GJ. Pharmacokinetic study of Rhein and its carboxyl- esterification derivatives in rats[J]. Chin J Nat Med，2009，7(3)：228-233.
[21]	ANAND BS，KATRAGADDA S，MITRA AK. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration：Intestinal absorption and liver metabolism[J]. J Pharmacol Exp Ther，2004，311(2)：659-667.
[22]	ZHANG MJ，LI W，WEN HM，et al. Synthesis and biological evaluation of liguzinediol mono- and dual ester prodrugs as promising inotropic agents[J]. Molecules，2014，19，18057-18072.